Preliminary results from a phase II study of the epidermal growth factor receptor tyrosine kinase inhibitor erlotinib in patients > 70 years of age with previously untreated advanced non-small cell lung carcinoma
暂无分享,去创建一个
P. Jänne | J. Temel | T. Lynch | Geoffrey Liu | M. Rabin | A. Skarin | J. Lucca | P. Ostler | B. Johnson